Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00823108 · ClinicalTrials.gov registry record · Phase 1
Rapid Administration of Insulin in Sepsis
A Phase 1 study, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT00823108 is a Phase 1 study that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 20 participants.
The verdict
NCT00823108, a Phase 1 study, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if a glucose-insulin-potassium (GIK) solution can be safely administered to patients with septic shock. GIK has been used in thousands of critically ill patients in research studies with very few safety concerns. However, there is a lack of data in regards to patients with septic shock. There are many reasons to believe that GIK would be beneficial in sepsis, including improving heart function and decreasing inflammation. This study will administer intravenous GIK for 12 hours continuously and monitor 10 subjects for 24 hours. A control arm will be used and 10 patients will receive the same monitoring but will not receive GIK.
Interventions
- DRUG GIK
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-03 |
| Est. Completion | 2010-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00823108
The ClinicalTrials.gov registry entry for NCT00823108 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which GIK is the first listed.
NCT00823108 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00823108 about?
NCT00823108 is a clinical study titled "Rapid Administration of Insulin in Sepsis". The purpose of this study is to determine if a glucose-insulin-potassium (GIK) solution can be safely administered to patients with septic shock. GIK has been used in thousands of critically ill patients in research studies with very few safety concerns. However, there is a lack of data in regards t...
What is the current status of trial NCT00823108?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-03. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00823108?
The interventions under investigation include: GIK (DRUG).
Who is sponsoring clinical trial NCT00823108?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.